92 related articles for article (PubMed ID: 4032714)
21. [Clinical study of S 6472 granule preparation (sustained-release cefaclor) in chronic respiratory airway infections].
Odagiri S; Matsunaga K; Suzuki K; Murohashi K; Numata H; Takahashi K; Yamaki I; Ishii S
Jpn J Antibiot; 1988 Sep; 41(9):1325-33. PubMed ID: 3241332
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of S 6472 granule preparation (sustained-release cefaclor) in chronic bronchitis].
Hiraga Y; Omichi M; Sasaoka S
Jpn J Antibiot; 1988 Sep; 41(9):1304-8. PubMed ID: 3241328
[TBL] [Abstract][Full Text] [Related]
23. [Fundamental and clinical studies of S 6472 (sustained release preparation of cefaclor) in the pediatric field].
Sugita M; Toyonaga Y; Nakamura H; Kurosu Y; Hori M
Jpn J Antibiot; 1985 Sep; 38(9):2444-52. PubMed ID: 3908736
[TBL] [Abstract][Full Text] [Related]
24. [Clinical examination of S 6472 (sustained release preparations of cefaclor on chronic respiratory tract infection].
Hayashi I; Ohnuma K
Jpn J Antibiot; 1988 Sep; 41(9):1313-8. PubMed ID: 3241330
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of multiple-dose cefprozil and comparison with cefaclor.
Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281
[TBL] [Abstract][Full Text] [Related]
26. [Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)].
Lode H; Stahlmann R; Dzwillo G; Koeppe P
Arzneimittelforschung; 1980; 30(3):505-9. PubMed ID: 7387765
[TBL] [Abstract][Full Text] [Related]
27. Serum and sputum levels of cefaclor.
Simon C; Gatzemeier U
Postgrad Med J; 1979; 55 Suppl 4():30-4. PubMed ID: 548940
[TBL] [Abstract][Full Text] [Related]
28. [Clinical evaluation of cefpodoxime proxetil in the treatment of skin and soft tissue infections. A double blind comparison of cefpodoxime proxetil and cefaclor].
Yura J; Shinagawa N; Mizuno A; Watanabe S; Ando M; Sakai K; Ueda T; Morimoto K; Nakamura T; Hashimoto I
Jpn J Antibiot; 1988 Oct; 41(10):1517-37. PubMed ID: 3060626
[TBL] [Abstract][Full Text] [Related]
29. [A double-blind comparative study of S 6472 (a long-acting cefaclor) versus a conventional cefaclor preparation in complicated urinary tract infections].
Arakawa S; Takagi S; Matsumoto O; Kamidono S; Hirooka K; Hamami G; Matsumoto H; Saito H; Umezu K; Ishigami J
Jpn J Antibiot; 1990 Nov; 43(11):1873-92. PubMed ID: 2287055
[TBL] [Abstract][Full Text] [Related]
30. [Clinical studies of cefaclor for respiratory tract infections].
Hiraga Y; Kikuchi K; Yamamoto A
Jpn J Antibiot; 1984 Apr; 37(4):581-8. PubMed ID: 6471379
[TBL] [Abstract][Full Text] [Related]
31. [Clinical studies on te concentration of cefaclor in sera and lung tissues of patients with respiratory diseases].
Imaizumi M; Kajita M; Fujita K; Niimi T; Kamiya I; Takahashi T; Asaoka M; Abe T
Jpn J Antibiot; 1986 Oct; 39(10):2754-60. PubMed ID: 3806958
[TBL] [Abstract][Full Text] [Related]
32. [Effect of cefaclor in urinary tract infections (2)].
Kajikawa H; Hosokawa S; Kameoka H; Nishimoto N; Miyoshi S; Iwao N; Mizutani S
Jpn J Antibiot; 1984 Aug; 37(8):1453-69. PubMed ID: 6502932
[TBL] [Abstract][Full Text] [Related]
33. [Clinical results of cefaclor treatment of infections of oral regions].
Yoshida Y; Kita T; Kanematsu N; Sato K; Kawata K; Fukuta N; Sato J
Jpn J Antibiot; 1984 Mar; 37(3):318-28. PubMed ID: 6737694
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
35. [A parallel comparative double blind study of cefixime with cefaclor in the treatment of acute suppurative otitis media in children].
Baba S; Kinoshita H; Mori Y; Suzuki K; Shimada J; Kawamura S; Onishi S; Ueda R; Kobayashi K; Itoh Y
Jpn J Antibiot; 1987 Jan; 40(1):1-24. PubMed ID: 3295321
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity and pharmacokinetics of cefaclor in normal volunteers and patients with renal failure.
Levison ME; Santoro J; Agarwal BN
Postgrad Med J; 1979; 55 Suppl 4():12-6. PubMed ID: 548939
[TBL] [Abstract][Full Text] [Related]
37. Suprofen sustained release kinetics in healthy male volunteers. 1st communication: a single dose open crossover bioavailability study of suprofen sustained release tablets versus capsules.
Michos N; Zulliger HW; Barkworth MF; Johnson KJ; Rehm KD; Töberich H; Klein G
Arzneimittelforschung; 1986 Jun; 36(6):941-8. PubMed ID: 3741528
[TBL] [Abstract][Full Text] [Related]
38. A multicentre trial of cefaclor advanced formulation versus cefaclor in the treatment of acute bronchitis.
Alanis A; Longest KA; Senetar JE; Dere WH
Postgrad Med J; 1992; 68 Suppl 3():S24-8, discussion S29. PubMed ID: 1287614
[TBL] [Abstract][Full Text] [Related]
39. The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin.
Welling PG; Dean S; Selen A; Kendall MJ; Wise R
Int J Clin Pharmacol Biopharm; 1979 Sep; 17(9):397-400. PubMed ID: 500261
[TBL] [Abstract][Full Text] [Related]
40. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
